{"id":"NCT02951988","sponsor":"Naurex, Inc, an affiliate of Allergan plc","briefTitle":"A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-13","primaryCompletion":"2019-02-22","completion":"2019-02-22","firstPosted":"2016-11-01","resultsPosted":"2020-03-09","lastUpdate":"2020-03-09"},"enrollment":1304,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"Rapastinel","otherNames":[]},{"type":"DRUG","name":"Placebo-matching Rapastinel","otherNames":[]}],"arms":[{"label":"Rapastinel 450 mg Weekly","type":"EXPERIMENTAL"},{"label":"Rapastinel 450 mg Every 2 Weeks","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the efficacy, safety and tolerability of rapastinel 450 milligrams (mg) intravenous (IV) once weekly or once every 2 weeks versus placebo as an adjunctive treatment to ongoing anti-depressive therapy (ADT) in the prevention of relapse in participants with Major Depressive Disorder (MDD).","primaryOutcome":{"measure":"Time to First Relapse During the First 52 Weeks of the Double-Blind Treatment Period","timeFrame":"52 Weeks","effectByArm":[{"arm":"Placebo","deltaMin":232,"sd":null},{"arm":"Rapastinel 450 mg Every 2 Weeks","deltaMin":225,"sd":null},{"arm":"Rapastinel 450 mg Weekly","deltaMin":336,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5305"},{"comp":"OG000 vs OG002","p":"0.4628"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":137,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.allerganclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":1304},"commonTop":["Upper respiratory tract infection","Headache","Nasopharyngitis","Dysgeusia","Insomnia"]}}